EvolusArticles & NewsHomeMedTech Marketplace Pipeline Medical Now Provides Jeuveau for the Treatment of Glabellar LinesPipeline Medical aggregates medical supplies and pharmaceuticals from various manufacturers, suppliers and distributors, providing customers with streamlined purchasing experience.HomeEvolus Expands International Presence with Nuceiva Launch in Great BritainEvolus launched commercial operations in Great Britain and shipped the first customer order for Nuceiva (botulinum toxin type A) last month.HomeEvolus Promotes Sandra Beaver as Chief Financial OfficerSandra Beaver brings more than 20 years of financial experience, driving company growth through strategic planning, long-range forecasting and more.HomeEvolus Completes Patient Enrollment for Extra-Strength Glabellar Line StudyThe study evaluates an "extra-strength" dose of Jeuveau for its safety, efficacy, duration of effect and potential clinical tradeoffs for patients when using the longer duration option.HomeEvolus Celebrates Third Anniversary of Jeuveau LaunchJeuveau (prabotulinumtoxinA-xvfs) has been available in the U.S. for three years as the injectable's parent company, Evolus, continues national and international expansion plans.HomeFirst Patient Enrolled in Evolus Jeuveau “Extra-Strength” Dose Trial“Enrolling the first patient in the ‘extra-strength’ trial marks an important milestone for Evolus—we are now one step closer to the possibility of fulfilling an unmet need in the aesthetic neurotoxin segment.”